Nurse Practitioner Program year 2024 Reported 2023–2024 Source: CMS Open Payments, 2026 publication

Trevor Spence

Nurse Practitioner Caldwell, ID Nurse Practitioner

NPI 1669063384 CMS profile 10500875

206 E Elm St, Caldwell, ID 83605

Open in the dashboard

General payments

$829

34 records reported · program years 2023–2024

Research payments

$0

Paid to them · None reported · program years 2023–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Trevor Spence of Caldwell, ID is reported in the CMS Open Payments database as having received $829 across 34 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $263 16
2023 General $566 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trevor Spence
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Trevor Spence were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Trevor Spence Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $566 $166 $54–$529 $160
2024 $263 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2024
  1. Stryker Corporation $555 26 payments
  2. Zimmer Biomet Holdings, Inc. $199 4 payments
  3. Ferring Pharmaceuticals Inc. $37 2 payments
  4. Bioventus LLC $22 1 payment
  5. Avanos Medical $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2024
  1. Food and Beverage $829 34 payments
Products named General payments · program years 2023–2024
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $258 5 payments
  2. TORNIER PERFORM REVERSED GLENOID $258 5 payments
  3. MAKO $157 12 payments
  4. TORNIER PERFORM REVERSED AUGMENTED GLENOID $99 2 payments
  5. Trabecular Metal $72 1 payment
  6. TORNIER FLEX $66 1 payment
  7. ACCOLADE $61 4 payments
  8. INSIGNIA $61 4 payments
  9. Comprehensive Shoulder System $58 1 payment
  10. ROSA $47 1 payment
  11. Other $215 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

522

Median for Nurse Practitioner: 389

Drug cost

$3,362

Median for Nurse Practitioner: $21,885

Branded share of claims

16.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 73 $911
Tramadol Hcl Generic 171 $778
Celecoxib Generic 12 $464
Oxycodone Hcl Generic 95 $448
Meloxicam Generic 60 $194
Fluticasone Propionate Generic 14 $123
Ondansetron Odt Ondansetron Brand 11 $121
Gabapentin Generic 12 $104
Cephalexin Generic 15 $69
Cyclobenzaprine Hcl Generic 14 $69

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$26,270

Of which drugs: $8,826

Medicare patients

186

Average age 75

Services billed

1,963

113 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 69%
High blood pressure 68%
Depression 23%
Diabetes 20%
Ischemic heart disease 19%
Chronic kidney disease 18%
Atrial fibrillation 15%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 20 912 $5,896
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 15 76 $96

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

34 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record